Diabetes Research and Clinical Practice
Volume 72, Issue 3 , Pages 258-264 , June 2006

Urinary TGF-β1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy

Received 27 May 2005 ,Revised 27 September 2005 ,Accepted 27 October 2005.

References 

  1. Border WA, Yamamoto T, Noble NA. Transforming growth factor beta in diabetic nephropathy. Diab. Metab. Rev. 1996;12:309–339
  2. Bertoluci MC, Schmid H, Lachat JJ, Coimbra TM. Transforming growth factor-beta in the development of rat diabetic nephropathy. Nephron. 1996;74:189–196
  3. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization by TGF-β antibody attenuates kidney hypertrophy and the enhanced extra-cellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 1996;45:522–530
  4. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnick BR, et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes. 1997;46:854–859
  5. Bertoluci MC, Schaan BD, Coimbra TM, Schmid H. Increased urinary TGF-β1 in type 2 diabetic patients with diabetic nephropathy. Diabetes. 1998;47(Suppl. 1):0504
  6. Bertoluci MC, Machado MP, Lima KM, Thome F, Barros E, Veronese F, et al. Increased urinary TGF-β1 in diabetic nephropathy in comparison to non-diabetic nephropathies. Diabetes. 2000;49(Suppl. 1):229-OR
  7. Ellis D, Forrest KY, Erbey J, Orchard TJ. Urinary measurement of transforming growth factor beta and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin.Chem. 1998;44:950–956
  8. Rivarola EWR, Moyses-Neto M, Dantas M, da Silva CG, Volpini R, Coimbra TM. Transforming growth factor beta activity in urine of patients with type 2 diabetes and diabetic nephropathy. Braz. J. Med. Biol. Res. 1999;32:1525–1528
  9. Sato H, Iwano M, Akai Y, Kurioka H, Kubo A, Yamaguchi T, et al. Increased excretion of urinary transforming growth factor beta-1 in patients with diabetic nephropathy. Am. J. Nephrol. 1988;18:490–494
  10. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2002;346:1145–1151
  11. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  12. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J. Clin. Invest. 1994;74:536–542
  13. Schaan BD, Lachchini S, Bertoluci MC, Irigoyen MC, Machado UF, Schmid H. Increased Renal GLUT1 abundance and Urinary TGF-β1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes. Horm. Metab. Res. 2001;33:6664–6669
  14. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 1986;77:1925–1930
  15. Krolewski AS, Canessa M, Warram JH, Laffel LMB, Christlieb R, Knowler WC, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1998;318:140–150
  16. Canani LH, Gerchman F, Gross JL. Familial clustering of diabetic nephropathy in brazilian type 2 diabetic patients. Diabetes. 1999;48:909–913
  17. Riser B, Ladson-Wofford S, Sharba A, Cortes P, Drake K, Guerin CJ, et al. TGF-β receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Kidney Int. 1999;56:428–439
  18. Riser BL, Cortes P, Heilig C, Grondin J, Ladson-Wofford S, Patterson D, et al. Cyclic stretching force selectively up-regulates transforming growth factor-β isoforms in cultured rat mesangial cells. Am. J. Pathol. 1996;148:1915–1923
  19. Wolf G. Link between angiotensin II and TGF-β in the kidney. Miner. Electrolyte Metab. 1998;24:174–180
  20. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001;345:861–869
  21. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Raz I: renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001;345:851–860
  22. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper MA, Jerums G, Gilbert RE. Urinary transforming growth factor β excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate. Diab. Care. 2002;25:1072–1077
  23. Iwano M, Kubo A, Nishino T, Sato H, Nishioka H, Akai Y, et al. Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus. Kidney Int. 1996;49:1120–1126
  24. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, et al. Captopril-induced reduction of serum levels of transforming growth factor-beta 1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am. J. Kidney Dis. 1999;34:818–823
  25. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes. 1993;42:450–456

PII: S0168-8227(05)00435-3

doi: 10.1016/j.diabres.2005.10.027

Diabetes Research and Clinical Practice
Volume 72, Issue 3 , Pages 258-264 , June 2006

Article Tools

* Image Usage & Resolution